Clinical observation of thalidomide combined with DICE scheme in the treatment of refractory recurrent non-Hodgkin lymphoma

Abstract

Objective \nTo investigate the efficacy of thalidomide combined with DICE scheme in the treatment of refractory recurrent non-hodgkin lymphoma patients and the occurrence of toxic and side effects. \n \n \nMethods \nClinical data of 96 patients with refractory and recurrent non-Hodgkin lymphoma treated in the Fifth People’s Hospital of Datong from May 2015 to July 2018 were retrospectively analyzed, according to the treatment method, they were divided into control group (DICE, 48 cases) and observation group (48 cases, degree of amine + DICE scheme). The clinical curative effect and adverse reaction between the two groups were compared. \n \n \nResults \nThe total effective rate in the observation group (60.42%) was higher than that in the control group(39.58%), and the difference was statistically significant (P 0.05). \n \n \nConclusions \nThalidomide is effective in the treatment of refractory recurrent non-Hodgkin lymphoma patients on the basis of DICE scheme, and it wouldn’t increase the severity of adverse effects. \n \n \nKey words: \nRefractory recurrent non-hodgkin’s lymphoma;\xa0Thalidomide;\xa0DICE scheme